vs
Capitol Federal Financial, Inc.（CFFN）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Capitol Federal Financial, Inc.的季度营收约是REGENXBIO Inc.的1.9倍（$57.7M vs $30.3M），Capitol Federal Financial, Inc.净利率更高（34.9% vs -221.3%，领先256.2%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 12.1%）
国会联邦储蓄银行（CapFed）成立于1893年，是获得联邦特许并承保的储蓄银行，总部位于堪萨斯州托皮卡。该行目前共有51个网点，覆盖堪萨斯城都会区的堪萨斯州与密苏里州两侧，为个人及企业提供各类金融服务，其控股公司国会联邦金融 Inc.在纳斯达克挂牌上市。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CFFN vs RGNX — 直观对比
营收规模更大
CFFN
是对方的1.9倍
$30.3M
净利率更高
CFFN
高出256.2%
-221.3%
两年增速更快
RGNX
近两年复合增速
12.1%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $57.7M | $30.3M |
| 净利润 | $20.1M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 34.9% | -221.3% |
| 营收同比 | — | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CFFNRGNX
| Q1 26 | $57.7M | — | ||
| Q4 25 | $56.8M | $30.3M | ||
| Q3 25 | $54.6M | $29.7M | ||
| Q2 25 | $50.7M | $21.4M | ||
| Q1 25 | $48.8M | $89.0M | ||
| Q4 24 | $46.9M | $21.2M | ||
| Q3 24 | — | $24.2M | ||
| Q2 24 | $45.0M | $22.3M |
净利润CFFNRGNX
| Q1 26 | $20.1M | — | ||
| Q4 25 | $20.3M | $-67.1M | ||
| Q3 25 | $18.8M | $-61.9M | ||
| Q2 25 | $18.4M | $-70.9M | ||
| Q1 25 | $15.4M | $6.1M | ||
| Q4 24 | $15.4M | $-51.2M | ||
| Q3 24 | — | $-59.6M | ||
| Q2 24 | $9.6M | $-53.0M |
毛利率CFFNRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率CFFNRGNX
| Q1 26 | — | — | ||
| Q4 25 | 44.4% | -190.0% | ||
| Q3 25 | 42.2% | -176.3% | ||
| Q2 25 | 42.6% | -296.3% | ||
| Q1 25 | 39.5% | 13.6% | ||
| Q4 24 | 40.7% | -242.1% | ||
| Q3 24 | — | -256.6% | ||
| Q2 24 | 34.7% | -251.3% |
净利率CFFNRGNX
| Q1 26 | 34.9% | — | ||
| Q4 25 | 35.7% | -221.3% | ||
| Q3 25 | 34.5% | -208.3% | ||
| Q2 25 | 36.2% | -331.8% | ||
| Q1 25 | 31.6% | 6.8% | ||
| Q4 24 | 32.9% | -241.3% | ||
| Q3 24 | — | -246.3% | ||
| Q2 24 | 21.4% | -237.7% |
每股收益（稀释后）CFFNRGNX
| Q1 26 | — | — | ||
| Q4 25 | $0.16 | $-1.30 | ||
| Q3 25 | $0.14 | $-1.20 | ||
| Q2 25 | $0.14 | $-1.38 | ||
| Q1 25 | $0.12 | $0.12 | ||
| Q4 24 | $0.12 | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | $0.07 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.0B | $102.7M |
| 总资产 | $9.8B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CFFNRGNX
| Q1 26 | $2.5M | — | ||
| Q4 25 | $232.6M | $230.1M | ||
| Q3 25 | $252.4M | $274.2M | ||
| Q2 25 | $175.0M | $323.3M | ||
| Q1 25 | $340.4M | $267.9M | ||
| Q4 24 | $170.3M | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | $317.8M | $290.4M |
股东权益CFFNRGNX
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.0B | $102.7M | ||
| Q3 25 | $1.0B | $161.5M | ||
| Q2 25 | $1.0B | $213.7M | ||
| Q1 25 | $1.0B | $274.2M | ||
| Q4 24 | $1.0B | $259.7M | ||
| Q3 24 | — | $301.4M | ||
| Q2 24 | $1.0B | $348.3M |
总资产CFFNRGNX
| Q1 26 | $9.8B | — | ||
| Q4 25 | $9.8B | $453.0M | ||
| Q3 25 | $9.8B | $525.2M | ||
| Q2 25 | $9.7B | $581.0M | ||
| Q1 25 | $9.7B | $490.9M | ||
| Q4 24 | $9.5B | $466.0M | ||
| Q3 24 | — | $519.1M | ||
| Q2 24 | $9.6B | $569.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CFFNRGNX
| Q1 26 | — | — | ||
| Q4 25 | $17.4M | $-52.3M | ||
| Q3 25 | $55.0M | $-56.0M | ||
| Q2 25 | $12.4M | $-49.3M | ||
| Q1 25 | $15.5M | $33.6M | ||
| Q4 24 | $5.6M | $-31.6M | ||
| Q3 24 | — | $-40.5M | ||
| Q2 24 | $19.1M | $-45.5M |
自由现金流CFFNRGNX
| Q1 26 | — | — | ||
| Q4 25 | $15.8M | $-52.8M | ||
| Q3 25 | $49.8M | $-56.5M | ||
| Q2 25 | $10.8M | $-49.7M | ||
| Q1 25 | $14.7M | $32.6M | ||
| Q4 24 | $4.5M | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | $16.4M | $-46.0M |
自由现金流率CFFNRGNX
| Q1 26 | — | — | ||
| Q4 25 | 27.9% | -174.0% | ||
| Q3 25 | 91.3% | -189.9% | ||
| Q2 25 | 21.2% | -232.8% | ||
| Q1 25 | 30.2% | 36.6% | ||
| Q4 24 | 9.5% | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | 36.5% | -206.2% |
资本支出强度CFFNRGNX
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | 1.7% | ||
| Q3 25 | 9.5% | 1.7% | ||
| Q2 25 | 3.2% | 1.8% | ||
| Q1 25 | 1.5% | 1.2% | ||
| Q4 24 | 2.5% | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | 5.9% | 2.1% |
现金转化率CFFNRGNX
| Q1 26 | — | — | ||
| Q4 25 | 0.86× | — | ||
| Q3 25 | 2.93× | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 1.01× | 5.53× | ||
| Q4 24 | 0.36× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.98× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CFFN
| Net Interest Income | $52.3M | 91% |
| Noninterest Income | $5.5M | 9% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
